Skip to Main Content

David Reese calls it a “hinge moment” — the turning point when biotech and big tech merge to attack human disease with artificial intelligence.

At Amgen, where he’s led drug research and development since 2018, Reese said this moment has finally arrived. The proof lies not only in organizational changes, such as his recent appointment as the company’s first chief technology officer, but also in Amgen’s broader push to embed AI into every aspect of the drug discovery process.

advertisement

“We’re now seeing 10-fold improvements in these (AI) models every six months,” said Reese, a medical oncologist by training. He added that the quickening pace of advancement means investing in the technology is no longer optional: “It’s something we must do to have a practical, pragmatic impact on drug discovery.”

STAT+ Exclusive Story

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $399/year

$30 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

To submit a correction request, please visit our Contact Us page.